


Sentimag® – Sienna+® / Magtrace™

Magnetic lymph node localisation for prostate cancer – Clinical results

Since the Sentimag® system was launched for lymph node localisation at the end of 2012, the system has been used to treat over 30,000 cancer patients and has produced a strong base of clinical results that confirms its safety and efficacy in the nodal staging of cancer. In prostate cancer, clinical studies involving 179 patients have demonstrated clinical efficacy of magnetic lymph node localisation. Sienna+® supports two different lymph node localisation approaches.


Sienna+® enhanced ePLND

Sienna+® can enhance standard extended pelvic lymph node dissection (ePLND). In the targeted staging approach, the magnetically marked lymph nodes are identified *ex vivo* from the pool of excised lymph nodes and analysed. This approach allows a targeted extensive lymph node analysis for an optimised staging while reducing the analysis workload.



Sienna+® sentinel PLND

Sienna+® can help to reduce the extent of lymph node dissection. In the sentinel PLND (sPLND) approach, which spares lymph nodes, only the magnetically marked sentinel lymph nodes are removed *in vivo* and analysed. This approach allows a targeted extensive lymph node analysis for an optimised staging and potentially reduces post-operative morbidity.



Magnetic lymph node localisation for prostate cancer – Clinical results

Publications

[1] Winter A, Engels S, Wawroschek F. (2017): Sentinel lymph node surgery in prostate cancer using magnetic particles. *Current Opinion in Urology*. 27:000–000, doi:10.1097/MOU.0000000000000480. [abstract]



[2] Winter A, Engels S, Reinhardt L, Wasylow C, Gerullis H, Wawroschek F. (2017): Magnetic Marking and Intraoperative Detection of Primary Draining Lymph Nodes in High-Risk Prostate Cancer Using Superparamagnetic Iron Oxide Nanoparticles: Additional Diagnostic Value. *Molecules*. 22(12), 2192, doi:10.3390/molecules22122192. [open access]

[3] Stanik M, Macík D, Čapák I, Marečková N, Lžičařova E, Doležel J. (2017): Sentinel lymph node dissection in prostate cancer using superparamagnetic particles of iron oxide: Early clinical experience. *European Urology Supplements*. 16(11):E2911. [abstract]



[4] Winter A, Kowald T, Paulo T, Goos P, Engels S, Gerullis H, Chavan A, Wawroschek F. (2016): Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles: The first in-human results. *European Urology Supplements*. 15(3):E1060. [abstract]

[5] Winter A, Woenckhaus J, Wawroschek F. (2014): A novel method for intraoperative sentinel lymph node detection in prostate cancer patients using superparamagnetic iron oxide nanoparticles and a handheld magnetometer: the initial clinical experience. *Annals of Surgical Oncology*. 21(13):4390 – 4396. [open access]



Last update July 2018

Endomag®, Sentimag®, Magseed® and Sienna+® are registered European Community Trademarks of Endomagnetics Ltd. · www.endomag.com

Distributor: Sysmex Europe GmbH

Bornbarch 1, 22848 Norderstedt, Germany · Phone +49 40 52726-0 · Fax +49 40 52726-100 · oncology@sysmex-europe.com · www.sysmex-europe.com

Manufacturer: Endomagnetics Ltd.

The Jeffreys Building, St John's Innovation Park, Cowley Road, Cambridge CB4 0WS, United Kingdom

You will find your local Sysmex representative's address under www.sysmex-europe.com/contacts